Published in Clin Pharmacol Ther on May 01, 1985
The role of human carboxylesterases in drug metabolism: have we overlooked their importance? Pharmacotherapy (2013) 1.37
Pharmacokinetics and pharmacodynamic modeling of direct suppression effects of methylprednisolone on serum cortisol and blood histamine in human subjects. Clin Pharmacol Ther (1989) 1.32
Methylprednisolone inhibits uptake of Ca2+ and Na+ ions into concanavalin A-stimulated thymocytes. Biochem J (1997) 0.86
Methylprednisolone pharmacokinetics after intravenous and oral administration. Br J Clin Pharmacol (1989) 0.86
Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment. Eur J Clin Pharmacol (2015) 0.75
Grapefruit-drug interactions: can interactions with drugs be avoided? J Clin Pharmacol (2006) 1.82
Incidence and natural history of phrenic neuropathy occurring during open heart surgery. Chest (1993) 1.68
Binding kinetics of fluticasone propionate to the human glucocorticoid receptor. Steroids (1994) 1.64
Classically and alternatively activated macrophages contribute to tissue remodelling after myocardial infarction. J Cell Mol Med (2009) 1.58
Pharmacokinetics and bioavailability of quercetin glycosides in humans. J Clin Pharmacol (2001) 1.57
AUIC--a general target for the optimization of dosing regimens of antibiotics? Ann Pharmacother (1996) 1.51
Pharmacokinetic characterization and tissue distribution of the new glucocorticoid soft drug loteprednol etabonate in rats and dogs. J Pharm Sci (1992) 1.45
Microbial symbionts of marine invertebrates: opportunities for microbial biotechnology. J Mol Microbiol Biotechnol (1999) 1.44
Systemic bioavailability of inhaled steroids: the importance of appropriate and comparable methodology. Eur Respir J (2001) 1.43
Tako-Tsubo cardiomyopathy: NT-proBNP as a reliable parameter of a favourable prognosis? Int J Cardiol (2007) 1.39
[Correlation of radiologic and pathologic-anatomical findings in dust-induced pneumoconiosis in former coal miners]. Pneumologie (1997) 1.39
Distribution of inhaled fluticasone propionate between human lung tissue and serum in vivo. Eur Respir J (1997) 1.36
Microdialysis in peripheral tissues. Adv Drug Deliv Rev (2000) 1.35
Microdialysis. A novel tool for clinical studies of anti-infective agents. Eur J Clin Pharmacol (2001) 1.34
Pharmacokinetics and pharmacodynamics of glucocorticoid suspensions after intra-articular administration. Clin Pharmacol Ther (1986) 1.32
Activation of beclomethasone dipropionate by hydrolysis to beclomethasone-17-monopropionate. Biopharm Drug Dispos (1990) 1.30
Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. Int J Clin Pharmacol Ther (1997) 1.25
Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. J Allergy Clin Immunol (1998) 1.24
Identification of glucocorticoid receptors in normal and neoplastic adult human lung. Res Exp Med (Berl) (1983) 1.17
Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration. Eur J Clin Pharmacol (1998) 1.17
Pharmacokinetic and pharmacodynamic changes in the elderly. Clinical implications. Clin Pharmacokinet (1998) 1.17
Pharmacokinetic/pharmacodynamic aspects of aerosol therapy using glucocorticoids as a model. J Clin Pharmacol (1997) 1.16
Pharmacokinetic/pharmacodynamic characteristics of the beta-2-agonists terbutaline, salbutamol and fenoterol. Int J Clin Pharmacol Ther Toxicol (1992) 1.07
Pharmacokinetics and oral bioavailability of hydrocortisone. J Clin Pharmacol (1991) 1.06
Pharmacokinetics of iron(III)-hydroxide sucrose complex after a single intravenous dose in healthy volunteers. Arzneimittelforschung (1996) 1.04
Population pharmacokinetics of intramuscular quinine in children with severe malaria. Antimicrob Agents Chemother (2001) 1.04
Pharmacokinetics of triamcinolone acetonide after intravenous, oral, and inhaled administration. J Clin Pharmacol (1995) 1.03
Penetration of cefaclor into the interstitial space fluid of skeletal muscle and lung tissue in rats. Pharm Res (2001) 1.02
Improvement of seminal parameters with Prelox: a randomized, double-blind, placebo-controlled, cross-over trial. Phytother Res (2009) 1.01
Hexanoate synthase, a specialized type I fatty acid synthase in aflatoxin B1 biosynthesis. Bioorg Chem (2001) 1.00
A combined in vivo pharmacokinetic-in vitro pharmacodynamic approach to simulate target site pharmacodynamics of antibiotics in humans. J Antimicrob Chemother (2000) 0.99
Pharmacokinetic-pharmacodynamic modeling of the antibiotic effect of piperacillin in vitro. Pharm Res (1996) 0.99
Determination of free interstitial concentrations of piperacillin-tazobactam combinations by microdialysis. J Antimicrob Chemother (1998) 0.98
Dynamic modeling of cortisol reduction after inhaled administration of fluticasone propionate. J Clin Pharmacol (1996) 0.98
Gender differences in pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther (1999) 0.97
Comparison of plasma and free tissue levels of ceftriaxone in rats by microdialysis. J Pharm Sci (1997) 0.97
Pharmacodynamics of methylprednisolone phosphate after single intravenous administration to healthy volunteers. Pharm Res (1991) 0.97
A sensitive LC-MS/MS method for the quantification of fluticasone propionate in human plasma. J Pharm Biomed Anal (2000) 0.95
Pharmacokinetics and pharmacodynamics of tilmicosin in sheep and cattle. J Vet Pharmacol Ther (1998) 0.94
Affinities of glucocorticoids for glucocorticoid receptors in the human lung. Agents Actions (1986) 0.94
Pharmacokinetics and bioavailability of the flavonol quercetin in humans. Int J Clin Pharmacol Ther (1999) 0.94
Bioavailability and pharmacokinetics of caffeoylquinic acids and flavonoids after oral administration of Artichoke leaf extracts in humans. Phytomedicine (2005) 0.94
Pharmacokinetic-pharmacodynamic modelling of the in vitro antiinfective effect of piperacillin-tazobactam combinations. Int J Clin Pharmacol Ther (1997) 0.93
Dependency of cortisol suppression on the administration time of inhaled corticosteroids. J Clin Pharmacol (1997) 0.93
Receptor-based pharmacokinetic-pharmacodynamic analysis of corticosteroids. J Clin Pharmacol (1993) 0.92
A pharmacokinetic/pharmacodynamic approach to predict the cumulative cortisol suppression of inhaled corticosteroids. J Pharmacokinet Biopharm (1999) 0.92
Determination of free extracellular concentrations of piperacillin by microdialysis. J Pharm Sci (1996) 0.92
An interactive algorithm for the assessment of cumulative cortisol suppression during inhaled corticosteroid therapy. AAPS PharmSci (2000) 0.92
Pharmacokinetics of triamcinolone acetonide and its phosphate ester. Eur J Clin Pharmacol (1985) 0.92
Endothelium-dependent vascular effects of Pycnogenol. J Cardiovasc Pharmacol (1998) 0.91
Orbital myositis as a paraneoplastic syndrome. Arch Ophthalmol (1994) 0.91
Simultaneous measurement of cortisol in serum and saliva after different forms of cortisol administration. Clin Chem (1992) 0.90
Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus or Turbohaler dry-powder inhalers to healthy subjects. J Clin Pharmacol (2001) 0.89
Biowaiver monographs for immediate release solid oral dosage forms: prednisolone. J Pharm Sci (2007) 0.89
Cramps and muscular pain: prevention with pycnogenol in normal subjects, venous patients, athletes, claudicants and in diabetic microangiopathy. Angiology (2006) 0.88
Rapid chromatographic determination of cefotaxime and its metabolite in biological fluids. J Chromatogr (1985) 0.88
Interpretation of absorption rate data for inhaled fluticasone propionate obtained in compartmental pharmacokinetic modeling. Int J Clin Pharmacol Ther (2005) 0.88
Binding kinetics of budesonide to the human glucocorticoid receptor. Eur J Pharm Sci (1998) 0.87
Prevention of venous thrombosis and thrombophlebitis in long-haul flights with pycnogenol. Clin Appl Thromb Hemost (2004) 0.87
Antiinflammatory activities of procyanidin-containing extracts from Pinus pinaster Ait. after oral and cutaneous application. Pharmazie (1997) 0.87
Pycnogenol for diabetic retinopathy. A review. Int Ophthalmol (2001) 0.87
Disposition of cefotaxime and its desacetyl metabolite in morbidly obese male and female subjects. Ther Drug Monit (1986) 0.87
HPLC determination of glucocorticoid alcohols, their phosphates and hydrocortisone in aqueous solutions and biological fluids. J Pharm Biomed Anal (1986) 0.87
A West Nile virus (WNV) recombinant canarypox virus vaccine elicits WNV-specific neutralizing antibodies and cell-mediated immune responses in the horse. Vet Immunol Immunopathol (2008) 0.86
Pharmacokinetics of methylprednisolone and prednisolone after single and multiple oral administration. J Clin Pharmacol (1997) 0.86
Clopidogrel in acute coronary syndrome: when, how much, how long? Z Kardiol (2005) 0.86
Urinary metabolites of French maritime pine bark extract in humans. Pharmazie (2000) 0.85
Pharmacokinetic-pharmacodynamic profile of systemic nitric oxide-synthase inhibition with L-NMMA in humans. Br J Clin Pharmacol (1999) 0.85
Treatment of osteoarthritis with Pycnogenol. The SVOS (San Valentino Osteo-arthrosis Study). Evaluation of signs, symptoms, physical performance and vascular aspects. Phytother Res (2008) 0.85
Desensitization of brain opiate receptor mechanisms by gonadal steroid treatments that stimulate luteinizing hormone secretion. Endocrinology (1988) 0.85
Pharmacokinetics of dexamethasone and its phosphate ester. Biopharm Drug Dispos (1987) 0.85
Evaluation of pulmonary absorption using pharmacokinetic methods. J Aerosol Med (2001) 0.85
Biochemical characterization of a glucocorticoid-induced membrane protein (RM3/1) in human monocytes and its application as model system for ranking glucocorticoid potency. Pharm Res (1998) 0.85
HPLC determination of dexamethasone in human plasma and its application to an in vitro release study from endovascular stents. Pharmazie (2006) 0.84
Mass spectra of 1-dimethylaminonaphthalene-5-sulphonyl derivatives of biogenic amines. Acta Pharm Suec (1968) 0.84
Pharmacokinetic properties of beta-lactamase inhibitors. Int J Clin Pharmacol Ther (1999) 0.84
Mass spectra of derivatives of phenylalkylamines. J Pharm Pharmacol (1968) 0.84
Pharmacokinetics of dichloroacetate in adult patients with lactic acidosis. J Clin Pharmacol (1997) 0.84
Pharmacokinetic/pharmacodynamic (PK/PD) evaluation of a once-daily treatment using ciprofloxacin in an extended-release dosage form. Infection (2005) 0.84
Simultaneous assay of propranolol, diltiazem and metabolites of diltiazem in human plasma by liquid chromatography. J Pharm Biomed Anal (1990) 0.84
Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone. Pharm Res (1995) 0.84
Improvement of signs and symptoms of chronic venous insufficiency and microangiopathy with Pycnogenol: a prospective, controlled study. Phytomedicine (2010) 0.84
Population pharmacokinetics of steady-state carbamazepine in Egyptian epilepsy patients. J Clin Pharm Ther (2011) 0.83